Condition: Endometrial Adenocarcinoma · Endometrial Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.
This description comes directly from the study's public registry record.
Wen X Liu, Doctor · +86 13702169191 · wenxin1973@163.com
Lu Sun · +86 18722068811 · sun_sl2006@126.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06917092